Zenotech Laboratories reported a net loss of Rs 1.07 crore for FY 2025-26, down from a profit of Rs 5.61 crore last year. Amid flat revenue of Rs 39.56 crore, the company has called an AGM for September 25, 2026, primarily to seek shareholder approval for material related party transactions with its parent firm, Sun Pharma, totaling Rs 200 crore. The board has opted against dividends.
Zenotech Laboratories FY26 Results and AGM Update
Revenue: Rs 39.56 crore | Net Loss: Rs 1.07 crore
Reader Takeaway: Continued dependence on Sun Pharma for revenue and critical operational funding via RPTs remains the central concern.
What just happened
Zenotech Laboratories has announced its financial results for FY 2025-26, reflecting a swing to a net loss of Rs 1.07 crore, despite revenue growing marginally by 1.5% to Rs 39.56 crore. The company has scheduled its Annual General Meeting (AGM) for September 25, 2026, conducted via video conferencing, to address key corporate resolutions including board appointments and substantial financial transactions.
Why this matters
The most significant item on the AGM agenda is the request for shareholder approval for material related party transactions with its holding company, Sun Pharmaceutical Industries Limited. These transactions, capped at Rs 200 crore, cover essential operational needs including conversion charges (Rs 60 crore), term loans (Rs 64 crore), equipment leasing (Rs 38 crore), and asset purchases. Given that 100% of Zenotech’s revenue is derived from Sun Pharma, this approval is vital for the company's operational continuity.
Corporate Governance Changes
- Mr. Nikkhil Venilal Kothhari was appointed as an Independent Director in January 2026, replacing Mr. Chintan Jitendra Shah, who retired.
- Mr. Jignesh Anantray Goradia is up for re-appointment at the upcoming AGM.
Risks to watch
The company remains heavily exposed to single-customer risk, as its entire business model relies on Sun Pharma. Furthermore, Zenotech continues to navigate legacy legal challenges concerning historical promoters and the status of defunct overseas subsidiaries, which remain a point of scrutiny for long-term investors.
What to track next
Investors should monitor the outcome of the RPT vote at the AGM and assess whether the company can stabilize its bottom line in the coming quarters, as persistent losses have led the board to pass on dividend payouts for the current period.